Skip to content
Screener

Alkermes ALKS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$32.9M+186%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$6.34M-67.7%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$0-100%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$347K-92.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$20.26M+1,474%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$23.6M-26.5%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+85.1%
Enterprise value$9.38B+133%
P/E125.9×+113×
P/S+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Sales and maturities of investments62,693195,078
Cash flows used in investing activities(2,079,411)(20,112)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares under share-based compensation arrangements42,00631,611
Proceeds from the issuance of debt, net1,511,557
Deferred financing costs paid to third parties(2,980)
Employee taxes paid related to net share settlement of equity awards(24,538)(30,459)
Payment for the repurchase of ordinary shares(27,696)

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's stock issuance proceeds?
Alkermes (ALKS) reported stock issuance proceeds of $26.29M in Q2 2026.
How has Alkermes's stock issuance proceeds changed year-over-year?
Alkermes's stock issuance proceeds increased by 1162.2% year-over-year, from $2.08M to $26.29M.
What is the long-term trend for Alkermes's stock issuance proceeds?
Over 4 years (2021 to 2025), Alkermes's stock issuance proceeds has grown at a 14.4% compound annual growth rate (CAGR), from $25.32M to $43.41M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Alkermes's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude